Fortrea Holdings Inc.

NASDAQ:FTRE

Biotechnology

Healthcare
$20.50 -0.46%

-$0.07 today

Market cap
$1.94B
Beta
2.11
P/E (TTM)
-3.1
EPS (TTM)
-$4.90
52W Low $4.36High $18.67

Volume 1.59M

Average 1.31M

FTRE Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Fortrea Holdings Inc.NASDAQ: FTRE

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue declines year over year

Q2 FY2026 revenue of $678.2M fell 4.5% year over year, behind the -2.1% change in trailing-twelve-month revenue. Sequentially, it rose 6.6% from the prior quarter. Over 3 fiscal years it compounded at -1.4% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 9 analysts of $2.68B (-1.7%) for the fiscal year ending Dec 2026, a slowdown from the +1.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$678.2M+6.6% QoQ
Last fiscal yearDec 2025
$2.72B+1.0% YoY
LTMJun 2026
$2.68B-2.1% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.5%-4.2%+0.3 pp
1 year+1.0%-1.7%-2.7 pp
3-year CAGR-1.4%+2.0%+3.3 pp
5-year CAGR+3.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
2.72B USD
Year-over-year change
+1.0%
4-year CAGR
-2.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How FTRE compares with its peers on the latest reported figures

  • FTRE's LTM Jun 2026 revenue of $2.68B is the 2nd highest of the 3 companies compared; the peer median is $1.63B.
  • Its year-over-year change of -2.1% is the lowest of 3, against a peer median of +13.4%.
  • Over three fiscal years its annual growth of -1.4% compares with a peer median of +13.9%.
FTRE Competitors Peer median
Revenue for FTRE and competitors
Company Period LTM YoY 3-year CAGR
MEDPMedpace Holdings, Inc.LTM Sep 2026$2.84B +20.4%+20.1%
FTREFortrea Holdings Inc.LTM Jun 2026$2.68B -2.1%-1.4%
CERTCertara, Inc.LTM Mar 2026$419.75M +6.4%+7.7%
Peer median (excluding FTRE) $1.63B+13.4%+13.9%

Competitors are the stored peer set for FTRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.06B2.84B2.84B2.7B2.72B
Cost of Revenue2.45B2.11B2.25B2.16B2.3B
Gross Profit604.4M724.4M590.6M534.2M425.8M
Gross Margin19.8%25.5%20.8%19.8%15.6%
Research & Development00000
Selling, General & Admin303.1M416.1M448.1M560.7M456.4M
Operating Expenses490.1M537.3M558.6M696.1M456.4M
Depreciation & Amortization166.3M93.6M98M86.9M78M
EBITDA302.9M280.8M137.2M(64.3M)(813.6M)
EBITDA Margin9.9%9.9%4.8%-2.4%-29.9%
Operating Income114.3M187.1M32M(161.9M)(30.6M)
Operating Margin3.7%6.6%1.1%-6.0%-1.1%
Interest Income00000
Interest Expense200K200K69.8M123.8M91.4M
Other Income / Expenses22.1M(100K)(62.5M)(113.1M)(952.4M)
Income Before Tax136.4M187M(30.5M)(275M)(983M)
Pre-Tax Margin4.5%6.6%-1.1%-10.2%-36.1%
Income Tax Expense38.4M41.1M1.2M(3.5M)3.2M
Net Income98M186.2M(25.2M)(328.5M)(986.2M)
Net Margin3.2%6.6%-0.9%-12.2%-36.2%
EPS (Basic)1.112.11(0.04)(3.67)(10.81)
EPS (Diluted)1.112.11(0.04)(3.67)(10.81)
Weighted Avg Shares88.4M88.4M88.8M89.5M91.2M
Weighted Avg Shares (Diluted)88.4M88.4M88.8M89.5M91.2M

Fortrea Holdings Inc.

NASDAQ:FTRE

Intrinsic Alpha fair value

Locked

Current Price

$20.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.